Arformoterol (tartrate)

Arformoterol (tartrate)

CAT N°: 23935
Price:

From 129.00 109.65

Aformoterol is the (R,R)-enantiomer of the ?2-adrenergic receptor (?2-AR) agonist formoterol (Item No. 15584).{43065} It selectively binds to ?1- over ?2-ARs (Kds = 2.9 and 113 nM, respectively) as well as ?3-adrenergic, B2 bradykinin, neurokinin 1 (NK1) and NK2 receptors when used at concentrations up to 3 ?M. Aformoterol induces cAMP accumulation in cultured human bronchial epithelial cells. Ex vivo, aformoterol (0.01-1,000 nM) induces dose-dependent relaxation of guinea pig tracheal strips precontracted with carbamoylcholine (Item No. 14486), ovalbumin, or histamine (pD2s = 8.4, 9.5, and 9.5, respectively). In vivo, aformoterol reverses histamine- and ovalbumin-induced bronchoconstriction in guinea pigs (ED50s = 1 and 40 nmol/kg, respectively). Formulations containing aformoterol have been used in the treatment of chronic obstructive pulmonary disease (COPD).

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-[2-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]phenyl]-formamide, (2R,3R)-2,3-dihydroxybutanedioate
  • Correlated keywords
    • 67346-49-0 208102-41-4 Brovana Nk-1 2 ?-1 ?-2 ?2AR ?1AR
  • Product Overview:
    Aformoterol is the (R,R)-enantiomer of the ?2-adrenergic receptor (?2-AR) agonist formoterol (Item No. 15584).{43065} It selectively binds to ?1- over ?2-ARs (Kds = 2.9 and 113 nM, respectively) as well as ?3-adrenergic, B2 bradykinin, neurokinin 1 (NK1) and NK2 receptors when used at concentrations up to 3 ?M. Aformoterol induces cAMP accumulation in cultured human bronchial epithelial cells. Ex vivo, aformoterol (0.01-1,000 nM) induces dose-dependent relaxation of guinea pig tracheal strips precontracted with carbamoylcholine (Item No. 14486), ovalbumin, or histamine (pD2s = 8.4, 9.5, and 9.5, respectively). In vivo, aformoterol reverses histamine- and ovalbumin-induced bronchoconstriction in guinea pigs (ED50s = 1 and 40 nmol/kg, respectively). Formulations containing aformoterol have been used in the treatment of chronic obstructive pulmonary disease (COPD).

We also advise you